Sherlock Bio Launches Clinical Trial Testing Rapid OTC STI Test

Reuters (5/30, Satija) reports, “Sherlock Bio said on Thursday it had begun a trial of its over-the-counter rapid test for detecting sexually transmitted infections (STI) such as chlamydia and gonorrhea, and aims to launch it by mid-2025.” The company “expects to become the first to launch a prescription-free rapid test for the infections, which affected 2.3 million people in the United States in 2022.” Sherlock “plans to recruit 2,500 sexually active volunteers at 20 study sites across the United States to test the accuracy of its CRISPR-based test compared to commonly used lab tests for chlamydia and gonorrhea.”